Abstract
Purpose and Scope of the Study This article is the product of eighteen months of analysis and research conducted through the joint efforts of Houlihan Valuation Advisors (HVA) and VentureOne undertaken to examine the question: What drives the pricing of venture capital (VC) investments in high technology and life sciences companies? In particular, we have attempted to explain changes in the value of venture capital-backed high technology and life sciences companies between the initial equity financing round (typically at inception date), interim financing rounds, and their initial public offering. The San Francisco-based investment research firm VentureOne has made available its proprietary database of venture capital investments in high tech and life sciences companies. HVA, a national securities valuation firm, has used this reliable source of information to examine venture investors' activity and identify key factors involved in the pricing of venture capital investments in these companies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
